Opthea Limited


Opthea Limited (ASX:OPT) is a biologics drug developer focusing on the therapies related to ophthalmic diseases. The group is having intellectual property protection around few Vascular Endothelial Growth Factors, namely, (VEGF)-C, VEGF-D and VEGFR-3; and Vegenics Pty Ltd., the subsidiary of Opthea holds the intellectual property rights. The technology under discussion, VEGF can regulate the blood as well as lymphatic vessel growth; and Opthea is focusing on developing its key product, OPT-302 (VGX-300, soluble VEGFR-3) that can cure wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which are known to be related to eye diseases.

Contact Information

company address Suite 0403, Level 4, 650 Chapel Street, SOUTH YARRA, VIC, AUSTRALIA, 3141

company phone(03) 9826 0399

company websitehttp://www.opthea.com

Similar Companies

Load More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK